Observational study to investigate safety and effectiveness of lorlatinib as first line treatment for ALK-gene rearranged unresectable advanced/recurrent NSCLC patients in Japan clinical setting

First published 05/06/2024

Last updated 23/04/2025

EU PAS number:

EUPAS1000000117

Study

Ongoing

Documents

Study protocol

Initial protocol

Non-Interventional Study Protocol_Ver1.0_reducted.pdf

English (430.63 KB - PDF)View document

Updated protocol

Non-Interventional Study Protocol_Ver2.0_reducted.pdf

First published: 04/06/2024

English (656.81 KB - PDF)View document

Study results

Study report

Other information

ENCePP Seal

ENCePP Seal documents

Secondary tabs